Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Luminex Corporation stock | $36.89

Learn how to easily invest in Luminex Corporation stock.

Luminex Corporation
NASDAQ: LMNX - USD
MEDICAL INSTRUMENTS & SUPPLIES
$0
-

Luminex Corporation is a medical instruments & supplies business based in the US. Luminex Corporation shares (LMNX) are listed on the NASDAQ and all prices are listed in US Dollars. Luminex Corporation employs 1,325 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Luminex Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LMNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Luminex Corporation stock price (NASDAQ: LMNX)

Use our graph to track the performance of LMNX stocks over time.

Luminex Corporation shares at a glance

Information last updated 2021-07-30.
Latest market close$36.89
52-week range$20.41 - $41.14
50-day moving average $36.84
200-day moving average $33.44
Wall St. target price$37.00
PE ratio 73.8323
Dividend yield $0.38 (1.03%)
Earnings per share (TTM) $0.50

Buy Luminex Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Luminex Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Luminex Corporation price performance over time

Historical closes compared with the close of $36.89 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 0.35%
3 months (2021-04-30) 0.55%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Is Luminex Corporation under- or over-valued?

Valuing Luminex Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Luminex Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Luminex Corporation's P/E ratio

Luminex Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 74x. In other words, Luminex Corporation shares trade at around 74x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Luminex Corporation's PEG ratio

Luminex Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Luminex Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Luminex Corporation's EBITDA

Luminex Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $85.6 million.

The EBITDA is a measure of a Luminex Corporation's overall financial performance and is widely used to measure a its profitability.

Luminex Corporation financials

Revenue TTM $437.7 million
Operating margin TTM 12.49%
Gross profit TTM $247.9 million
Return on assets TTM 5.06%
Return on equity TTM 4.97%
Profit margin 5.39%
Book value $10.55
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Luminex Corporation shares

There are currently 2.0 million Luminex Corporation shares held short by investors – that's known as Luminex Corporation's "short interest". This figure is 8.9% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Luminex Corporation shares can be evaluated.

Luminex Corporation's "short interest ratio" (SIR)

Luminex Corporation's "short interest ratio" (SIR) is the quantity of Luminex Corporation shares currently shorted divided by the average quantity of Luminex Corporation shares traded daily (recently around 403664.07185629). Luminex Corporation's SIR currently stands at 5.01. In other words for every 100,000 Luminex Corporation shares traded daily on the market, roughly 5010 shares are currently held short.

However Luminex Corporation's short interest can also be evaluated against the total number of Luminex Corporation shares, or, against the total number of tradable Luminex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Luminex Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Luminex Corporation shares in existence, roughly 40 shares are currently held short) or 0.0484% of the tradable shares (for every 100,000 tradable Luminex Corporation shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Luminex Corporation.

Find out more about how you can short Luminex Corporation stock.

Luminex Corporation share dividends

2%

Dividend payout ratio: 1.63% of net profits

Recently Luminex Corporation has paid out, on average, around 1.63% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Luminex Corporation shareholders could enjoy a 1.08% return on their shares, in the form of dividend payments. In Luminex Corporation's case, that would currently equate to about $0.38 per share.

While Luminex Corporation's payout ratio might seem low, this can signify that Luminex Corporation is investing more in its future growth.

Luminex Corporation's most recent dividend payout was on 7 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 June 2021 (the "ex-dividend date").

Luminex Corporation share price volatility

Over the last 12 months, Luminex Corporation's shares have ranged in value from as little as $20.4101 up to $41.135. A popular way to gauge a stock's volatility is its "beta".

LMNX.US volatility(beta: 0.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Luminex Corporation's is 0.5734. This would suggest that Luminex Corporation's shares are less volatile than average (for this exchange).

Luminex Corporation overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas. .

Frequently asked questions

What percentage of Luminex Corporation is owned by insiders or institutions?
Currently 4.354% of Luminex Corporation shares are held by insiders and 92.552% by institutions.
How many people work for Luminex Corporation?
Latest data suggests 1,325 work at Luminex Corporation.
When does the fiscal year end for Luminex Corporation?
Luminex Corporation's fiscal year ends in December.
Where is Luminex Corporation based?
Luminex Corporation's address is: 12212 Technology Boulevard, Austin, TX, United States, 78727
What is Luminex Corporation's ISIN number?
Luminex Corporation's international securities identification number is: US55027E1029
What is Luminex Corporation's CUSIP number?
Luminex Corporation's Committee on Uniform Securities Identification Procedures number is: 55027E102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site